Skip to content

Scholar Rock announces completion of TOPAZ trial enrollment

Scholar Rock announced today that enrollment of its TOPAZ Phase 2 trial of SRK-015 in patients with Type 2 and Type 3 SMA is complete. SRK-015 is a selective inhibitor of myostatin that has been shown to increase muscle mass and strength in animal models.

For more information, please see the press release from Scholar Rock.

Scroll To Top